In the past decade, one of the major advances in the management of patients with
symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents …

Oral mucositis (OM) is a debilitating early adverse effect of allogeneic hematopoietic stem
cell transplantation (HSCT). The intensity of the conditioning regimen correlates with the …

Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS) has been performed primarily with an HLA-matched …

Summary Background The Myeloma X trial previously reported improved durability of
response (time to disease progression) in patients with relapsed multiple myeloma with …

The nitrogen mustards are powerful cytotoxic and lymphoablative agents and have been
used for more than 60 years. They are employed in the treatment of cancers, sarcomas, and …

We previously described clinically relevant reductions in fecal microbiota diversity in patients
undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Recipients of high …

Background Retrospective studies suggest that conditioning therapy with busulfan plus
melphalan could result in longer progression-free survival compared with melphalan alone …

Purpose: The onset of drug resistance is a major cause of treatment failure in multiple
myeloma. Although increasing evidence is defining the role of miRNAs in mediating drug …

From the 1960s to the early 2000s, alkylating agents (eg, melphalan, cyclophosphamide,
and bendamustine) remained a key component of standard therapy for newly-diagnosed or …

Conditioning regimens play a crucial role in preventing relapse of acute myeloid leukemia
(AML) following allogeneic hematopoietic cell transplantation (HCT). In early times …